|
Video: What is a Stock Split?
|
|
Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Co. is developing antisense oligonucleotides to selectively restore protein levels. Co.'s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Co.'s second product candidate, STK-002, is in development for treatment of Autosomal Dominant Optic Atrophy. According to our Stoke Therapeutics stock split history records, Stoke Therapeutics has had 0 splits. | |
|
Stoke Therapeutics (STOK) has 0 splits in our Stoke Therapeutics stock split history database.
Looking at the Stoke Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Stoke Therapeutics shares, starting with a $10,000 purchase of STOK, presented on a split-history-adjusted basis factoring in the complete Stoke Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/20/2019 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$26.00 |
|
End price/share: |
$12.02 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-53.77% |
|
Average Annual Total Return: |
-14.64% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,623.13 |
|
Years: |
4.87 |
|
|
|
|
|